Array Biopharma (ARRY) Tops Q3 EPS by 38c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.39 -4.78%
EPS Growth %: -70.0%
Financial Fact:
Interest expense: -2.98M
Today's EPS Names:
OPY, BNCC, ZVOI, More
EPS Growth %: -70.0%
Financial Fact:
Interest expense: -2.98M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q3 EPS of $0.37, $0.38 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $6.6 million versus the consensus estimate of $6 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Goldman Sachs Revises China Jewelry Stocks Amid Gold Price Retreat
- John B. Sanfilippo & Son, Inc. (JBSS) PT Lowered to $79 at Freedom Broker
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
